Assuming two procedures over a 1-year time horizon, TearCare demonstrated a cost-saving advantage over CsA, reducing per-patient costs by $903 annually. Patients receiving TearCare experienced an ...
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial The economic evaluation, conducted from societal ...
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial For the model, we used ...
Trabeculectomy as a first-line procedure to treat glaucoma is more cost-effective than tube shunt surgery for people with elevated intraocular pressure (IOP), but tube shunt surgery may be the better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results